We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.34%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.32B
AUM Growth
+$623M
(+13%)
Cap. Flow
+$473M
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
31.02%
Holding
1,563
New
308
Increased
332
Reduced
859
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$43.7M |
| 2 |
American Tower
AMT
|
+$34.7M |
| 3 |
Crown Castle
CCI
|
+$21.3M |
| 4 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$19.1M |
| 5 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$80.9M |
| 2 |
Microsoft
MSFT
|
+$63.9M |
| 3 |
Amazon
AMZN
|
+$61.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$26.4M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$24.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.33% |
| 2 | Technology | 16.44% |
| 3 | Consumer Discretionary | 8.8% |
| 4 | Healthcare | 7.69% |
| 5 | Communication Services | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSXP
1251
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $74K | ﹤0.01% |
2,800
-250
| -8% | -$6.51K |
|
1252
MacroGenics
MGNX
$233M
| $73K | ﹤0.01% |
3,185
+2,072
| +186% | +$47.7K |
|
1253
Xencor
XNCR
$1.45B
| $73K | ﹤0.01% |
1,682
-458
| -21% | -$18.9K |
|
|
GTHX
1254
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $73K | ﹤0.01% |
4,076
+2,766
| +211% | +$41.3K |
|
|
IMGN
1255
DELISTED
Immunogen Inc
IMGN
| $73K | ﹤0.01% |
11,286
+148
| +1% | +$863 |
|
|
DRNA
1256
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $70K | ﹤0.01% |
3,184
+148
| +5% | +$3.26K |
|
1257
Alector
ALEC
$169M
| $69K | ﹤0.01% |
4,554
+2,726
| +149% | +$33.9K |
|
1258
Telus
TU
$17.4B
| $69K | ﹤0.01% |
+3,488
| New | +$65.7K |
|
|
NS
1259
DELISTED
NuStar Energy L.P.
NS
| $68K | ﹤0.01% |
4,703
-505
| -10% | -$6.47K |
|
1260
Globant
GLOB
$1.65B
| $67K | ﹤0.01% |
+307
| New | +$59.3K |
|
|
TBIO
1261
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $67K | ﹤0.01% |
3,640
+1,876
| +106% | +$33.6K |
|
|
CNST
1262
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $67K | ﹤0.01% |
2,312
+592
| +34% | +$14.9K |
|
1263
Celldex Therapeutics
CLDX
$2.94B
| $64K | ﹤0.01% |
+3,656
| New | +$65.8K |
|
1264
Relay Therapeutics
RLAY
$4B
| $64K | ﹤0.01% |
+1,549
| New | +$70K |
|
|
SHLX
1265
DELISTED
Shell Midstream Partners, L.P.
SHLX
| $61K | ﹤0.01% |
6,043
-402
| -6% | -$3.92K |
|
1266
Atara Biotherapeutics
ATRA
$72.6M
| $60K | ﹤0.01% |
122
-37
| -23% | -$17.1K |
|
|
EPZM
1267
DELISTED
Epizyme, Inc
EPZM
| $60K | ﹤0.01% |
5,508
+1,409
| +34% | +$17.4K |
|
|
ADVM
1268
DELISTED
Adverum Biotechnologies
ADVM
| $58K | ﹤0.01% |
535
+154
| +40% | +$19.1K |
|
|
KDMN
1269
DELISTED
Kadmon Holdings, Inc.
KDMN
| $58K | ﹤0.01% |
13,961
+5,813
| +71% | +$22.9K |
|
1270
Myriad Genetics
MYGN
$476M
| $57K | ﹤0.01% |
2,906
-2,936
| -50% | -$47.4K |
|
1271
Syndax Pharmaceuticals
SNDX
$1.7B
| $56K | ﹤0.01% |
+2,536
| New | +$52.6K |
|
1272
Tootsie Roll Industries
TR
$2.97B
| $55K | ﹤0.01% |
2,217
-2,552
| -54% | -$65.7K |
|
1273
Arcturus Therapeutics
ARCT
$165M
| $54K | ﹤0.01% |
+1,246
| New | +$84.4K |
|
1274
Rocket Pharmaceuticals
RCKT
$343M
| $54K | ﹤0.01% |
983
-650
| -40% | -$23.7K |
|
1275
Arcus Biosciences
RCUS
$3.33B
| $54K | ﹤0.01% |
2,079
+338
| +19% | +$8.18K |
|
Similar funds
SAM
Pacer Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Pacer Advisors held 1,563 positions worth $5.32B, up 13% from $4.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pacer Advisors deployed $473M of net new capital in Q4 2020, opening 308 new positions and adding to 332 existing holdings. Its largest new stake was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $80.9M trimmed.
- Pacer Advisors's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
- Pacer Advisors added most to Equinix in Q4 2020, an estimated $43.7M increase.
- Pacer Advisors's biggest Q4 2020 reduction was Apple, cutting an estimated $80.9M.
- Pacer Advisors fully exited INDUS Realty Trust, Inc. (MD) Common Stock in Q4 2020, selling an estimated $1.83M.
- Pacer Advisors's ten largest holdings make up 31% of its $5.32B portfolio in Q4 2020.
- Pacer Advisors opened 308 new positions and closed 60 in Q4 2020.
- Pacer Advisors's portfolio value rose 13% quarter-over-quarter to $5.32B.
Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.